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Abstract.  Modulation of endothelial cell proliferation 
and cell cycle progression by the "chemokine" platelet 
factor-4 (PF-4) was investigated. PF-4 inhibited DNA 
synthesis, as well as proliferation of endothelial cells 
derived from large and small blood vessels. Inhibition 
by PF-4 was independent of the type and the concen- 
tration of stimuli used for the induction of endothelial 
cell proliferation. Inhibition of cell growth by PF-4 
was reversible. The effects of PF-4 were antagonized 
by heparin. Cell cycle analysis using [3H]thymidine 
pulse labeling during traverse of synchronous cells 
from G0/G1  to S phase revealed that addition of PF-4 
during G1 phase completely abolished the entry of 
cells into S phase. In addition, PF-4 also inhibited 
DNA synthesis in cells that were already in S phase. 
In exponentially growing cells, addition of PF-4 
resulted in an accumulation of >70 % of the cells in 
early S phase, as determined by FACS  ® (Becton- 
Dickinson Immunocytometry Systems, Mountain 
View, CA). In cells synchronized in S phase by 
hydroxyurea and then released, addition of PF-4 
promptly blocked further progression of DNA synthe- 
sis.  These results demonstrate that in GO/Gl-arrested 
cells, PF-4 inhibited entry of endothelial cells into S 
phase. More strikingly, our studies have revealed a 
unique mode of endothelial cell growth inhibition 
whereby PF-4 effectively blocked cell cycle progres- 
sion during S phase. 
p 
LATELET factor-4 (PF-4) ~ is a member of a growing 
family of small, inducible proteins known as "chemo- 
kines" that mediate a variety of biological processes 
including inflammation, tissue repair, angiogenesis, and cell 
proliferation  (21, 4, 31). To date, more than 16 members of 
the supergene family have been identified (21). The members 
are classified as ct or/3, based on the nature of a highly con- 
served cysteine motif present at the NH2-terminal.  The o~ 
gene family characterized  by CXC motif  (cysteines separated 
by an amino acid) includes PF-4, IL-8, human protooncogene 
Gro/melanocyte growth-stimulating activity,/3-thromboglob- 
ulin,  neutrophil-activating  protein-2,  neutrophil  activating 
protein  from  epithelial  cells  (ENA-78),  and  interferon- 
inducing protein-10 (1, 15, 21, 24, 32, 34). The predominant 
activities  associated  with the CXC family of proteins are 
chemoattraction, and activation  of neutrophils  but not of 
monocytes (24).  The 13 gene family characterized by CC 
motif (adjacent cysteines)  includes monocyte chemotactic 
protein-I,  RANTES,  and macrophage inflammatory pro- 
teins-lct and -1/3 (MIP-lct and MIP-1/3) (13, 20, 21, 27). The 
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CC family of proteins stimulate chemotaxis in monocytes or 
T cells but not in neutrophils (13, 24, 33, 34). Other biologi- 
cal activities and physiological functions of the protein prod- 
ucts of the chemokine supergene family are currently under 
investigation. 
Human PF-4 is a 7.8-kD protein containing 70 amino acid 
residues (7).  PF-4  shares  31%, 41%,  and 51%  homology 
with IL-8, human protooncogene Gro/melanocyte growth- 
stimulating  activity,  and  jS-thromboglobulin,  respectively 
(21, 24, 31). Recent studies have revealed that PF-4 is an im- 
portant modulator of endothelial cell proliferation  (16) and 
angiogenesis (16, 17, 28). Purified recombinant human PF-4 
blocked proliferation  of human umbilical  vein endothelial 
cells in a dose-dependent manner (16). Intralesional  injec- 
tion of recombinant PF-4 also reduced tumor growth in syn- 
geneic C57BL/6J  mice with B-16(FI0) melanoma cell im- 
plants,  as well as in semisyngeneic  (CB/B6F1/J) athymic 
nude mice receiving primary cutaneous implants  of HCT 
116 colon carcinoma cells (16, 17, 28).  Since PF-4 did not 
directly inhibit B-16(F10) or HTC-116 cells in culture, these 
studies have concluded that the inhibition of tumor develop- 
ment by recombinant PF-4 was caused by its direct effect on 
endothelial cells and angiogenesis. In this regard, the actions 
of PF-4 are unique as compared to the other endothelial cell 
growth inhibitors such as TGF-/3 and TNF. Both TGF-/3 and 
TNF inhibit endothelial cell proliferation  in vitro (12, 22); 
however, these cytokines promote angiogenesis in vivo (9, 
10, 26). 
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cellular receptor and the mechanism of action on endothelial 
cells, have not been characterized. In the present study, we 
show that PF-4 exhibits a  unique mode of action on cell 
growth cycle in endothelial cells. PF-4 inhibits endothelial 
cell proliferation by blocking cell cycle traverse from G1 to 
S phase. More importantly, our studies show that PF-4 inhib- 
its progression of cells already in the DNA synthesis phase. 
The latter is a unique action of PF-4. An endogenous cyto- 
kine inhibiting cells in the S phase has not been previously 
described. 
Materials and Methods 
Cell Cultures 
EndothelialCells.  Retinal capillary endothelial cell cultures were obtained 
from Dr.  Larry Stramm (Eli Lilly and Company,  Indianapolis,  IN).  Cul- 
tures were initiated from bovine eyes using a modification of the procedure 
of Buzney et al. (3). Dispersed cells were separated from contaminating  cell 
types using a  fluorescent  cell sorter.  Cell cultures were  maintained in 
growth medium consisting of DME,  10% FBS, 2 mM,  L-glutamine,  100 
U/ml penicillin, and 100 #g/ml streptomycin.  Human aorta and umbilical 
cord endothelial cells were obtained from Clonetics Corp. (San Diego, CA). 
These cells were maintained in endothelial growth medium (EGM) supplied 
by Clonetics Inc. Fetal bovine heart endothelial (FBHE) cells were obtained 
from (American Type Culture Collection, Rockville,  MD). Stock cultures 
were propagated in medium containing 10% serum. Cultures were passaged 
once a week by trypsinization. 
Vascular Smooth Muscle Cells.  Smooth muscle cells were prepared 
from New Zealand white rabbits as described previously  (2). Aorta were 
removed aseptically, adventitia was stripped off, and 1-2-mm explants were 
cultured in DME containing 10% FBS, 2 mM L-glntamine, 100 U/ml peni- 
cillin, and 100 #g/ml streptomycin.  Smooth muscle cells were observed 
growing  from the explants within 5-7 d. After 7-10 d, explants were re- 
moved, and cells were subcultured  by trypsinization and propagated  in the 
above medium. 
Determination of DNA Synthesis 
Endothelial cells were plated in 96-well  plates at a  starting density of 
4  x  103 in DME containing 10% FBS. The cultures reached confluence 
after 5 d, at which time the medium was replaced with fresh DME contain- 
ing 10% FBS, 20 ng/ml basic FGF,  1 #Ci/ml [3H]thymidine,  and various 
concentrations of PF-4. For determination of entry into S phase, cells were 
pulsed with [3H]thymidine for 3-h intervals.  At the indicated time points, 
cells were fixed in methanol, and radioactivity  was determined by scintilla- 
tion counting (30). 
Determination of Cell Cycle Progression 
in Endothelial Cells 
For determination of entry of cells into S phase, confluent cultures  of en- 
dothelial cells were growth arrested by overnight incubation in DME con- 
taining 10% FBS without FGE Cells were then stimulated  with FGF (20 
ng/ml, and PF-4 was added at various intervals thereafter.  DNA synthesis 
was determined by pulse labeling with 1 #Ci/mi [3H]thymidine for 3-h in- 
tervals. For determination of the effect of PF-4 on S phase, endothelial cells 
were plated at a cell density of 4  ×  103 in 96-well microtiter plates.  After 
4 d, when the cultures were still nonconfluent, cells were synchronized  in 
S phase by incubation with 1 mM hydroxyurea for 24 h. Cell synchronicity 
in S phase was determined by (FACS®); (Becton Dickinson Immunocytom- 
etry  Systems,  Mountain View, CA).  DNA  synthesis  after release from 
hydroxyurea arrest was determined by pulse labeling with [3H]thymidine at 
1.5-h intervals  during S phase. 
FACS  ~ Analysis 
Fetal bovine heart endothelial cells were plated at a cell density of 5  ×  104 
cells per well in six-well plates in DME containing 10% FBS. After 24 h, 
duplicate cultures were supplemented with fresh medium containing 10% 
serum, 20 ng/ml FGF with or without PF-4.  The cultures were then in- 
cubated for additional 40 h. Ceils were harvested by trypsinization, washed 
in DME/10%  serum, and then fixed for 2 minutes with 70% methanol. 
Ceils were permeabilized by incubation in 0.1% Triton X-100 in phosphate- 
buffered saline for 15 rain, and were then treated with RNAse (200 ~g/ml). 
DNA was stained with propidium iodide (50 t~g/ml) by overnight incubation 
at 4°C in the dark. DNA content was determined by flow cytometry. Results 
were analyzed by the Modtit cell cycle analysis program (Varity Software 
Inc., Topshan,  NE). 
Materials. FGF, PDGF, and endothelial cell growth factor (ECGF) were 
purchased from Genzyme Corp. (Cambridge,  MA). PF-4 purified to homo- 
geneity  was from Sigma Immunochemicals (St.  Louis,  MO).  [3H]thymi- 
dine (specific activity  =  6.7 #Ci/mmol) was from New England Nuclear/ 
Dupont (Boston, MA). 
Results 
PF-4 Inhibits Proliferation  of Various 7)2pes 
of Endothelial Cells 
Endothelial cells from large vessels (human aorta, fetal bo- 
vine heart,  and human umbilical cord)  and microvessels 
(bovine retina) were cultured in DME containing 10% fetal 
bovine serum and basic FGE Addition of PF-4 at the time 
of plating or 6-24 h thereafter produced a dose-dependent 
inhibition of  cell proliferation during a 4-d incubation period 
(Fig. 1). The concentration of PF-4 required for 50 % inhibi- 
tion of endothelial cell growth was in the range of 1-3 ~g/ml. 
An apparent higher concentration of PF-4 required for hu- 
man aortic cells, as compared to the retinal or heart en- 
dothelial cells, is related to a significantly lower growth rate 
of aortic endothelial cells. For example, during the 4-d incu- 
bation period,  human aortic  endothelial cells  underwent 
only about two doublings, an increasing in cell number from 
1 ×  104 to 4.3  x  104, whereas retinal and heart endothelial 
cells  increased  from  lxl04  to  ll.2x104  and  12.5  104, 
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Figure 1. Inhibition of various types of endothelial cell proliferation 
by  PF-4.  Endothelial  cells  from  human aorta  (1),  fetal bovine 
heart  (o),  bovine retina (A),  and vascular smooth muscle cells 
from rabbit aorta (e) were cultured in 12-well plates at a cell den- 
sity of 1  x  104 per well in growth medium containing 20 ng/ml 
FGE The indicated concentration of homogeneously purified hu- 
man PF-4 was added at the start of the incubation. Cells were then 
incubated for 4  d  at 37°C  under 5%  CO2/95%  air.  Cell growth 
was determined by cell counting using a  Coulter counter. 
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a selective action of PF-4. Other members of the chemokine 
family (IL-8 and monocyte chemotactic protein-l) have not 
shown similar effects on endothelial cell proliferation (un- 
published results). Fig. 1 also shows that under identical cul- 
ture conditions, the growth of vascular smooth muscle cells 
was not inhibited by PF-4. These results show that PF-4 in- 
hibited proliferation of endothelial cells derived from large 
and  small  vessels.  Since  the  growth  of FBHE  cells  was 
strictly dependent on the presence of FGF and, thus, a highly 
synchronous cultures of these cells is obtained by depriving 
them of FGF,  we  have used  heart  endothelial  cells  for a 
detailed characterization of the mechanism of growth inhibi- 
tion by PF-4. 
Kinetics of FBHE Cell Growth Inhibition by PF-4 
Fig. 2 shows the rate of FBHE cell proliferation in the pres- 
ence of various concentrations of PF-4.  PF-4 produced a 
dose-dependent inhibition of cell proliferation that persisted 
throughout the 4-d incubation. PF-4 did not significantly al- 
ter the normal doubling time (18 +  2 h) of endothelial cells, 
suggesting that the effect of PF-4 was not simply caused by 
delaying the cell division cycle. Instead, in an exponentially 
growing culture, PF-4 appeared to have reduced the fraction 
of cycling cells. These data are also supported by inhibition 
of  DNA  synthesis  by  PF-4  during  extended  incubation. 
Growth-arrested FBHE enter the DNA synthesis phase •12 
h after stimulation with FGF. As shown in Fig. 2, inset, PF-4 
produced  a  dose-dependent  inhibition  of DNA  synthesis, 
even <24 h after FGF stimulation. These data suggest that 
PF-4 reduces the number of cycling cells without affecting 
their doubling time. 
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Figure 2. Kinetics of endothelial  cell growth inhibition by PF-4. 
FBHE ceils were plated  in growth medium containing  20 ng/ml 
FGF in the absence (e) or presence of 0.5 #g/ml (<>), 1/~g/ml (zx), 
or 2 /zg/ml (A) PF-4,  as described  in the legend to Fig.  1.  Also 
shown here is the growth of FBHE cells in the absence of FGF 
(i). Cells were harvested at the indicated time points by trypsini- 
zation  and  then  counted.  (Inset) Dose-dependent  inhibition  of 
DNA synthesis  in fetal bovine  heart  endothelial  cells  by PF-4. 
Growth-arrested  quiescent cells in 96-well microtiter plates were 
transferred to fresh medium containing 20 ng/ml FGF and various 
concentrations  of PF-4.  Cumulative DNA synthesis at the end of 
24-h incubation was determined  by [3H]thymidine incorporation, 
as described  under Materials  and Methods. 
Inhibition of Endothelial Cell Proliferation  by PF-4 is 
Independent of the Nature of the Growth Stimuli 
To obtain an initial insight into the cellular site of PF-4 ac- 
tion, and to rule out the potential effect of PF-4 on extracellu- 
lar action of FGE we determined the effect of PF-4 on en- 
dothelial cells stimulated with different growth stimuli, e.g., 
FGE ECGE or EGM, a medium containing a mixture of en- 
dothelial cell growth stimuli. Fig. 3 A shows that irrespective 
of the nature  of the growth stimuli used,  PF-4 effectively 
blocked endothelial cell proliferation. A slightly lower inhi- 
bition by PF-4 in cultures stimulated with ECGF was related 
to a slower growth of cells in medium containing ECFG, as 
compared to FGF or EGM. The results in Fig. 3 B show that 
increasing the FGF concentration while keeping the concen- 
tration of PF-4 constant did not reverse the growth inhibitory 
effect of PF-4, suggesting that the growth inhibitory effect of 
PF-4 was not simply by competition with FGE For example, 
a PF-4 concentration that produced 50% inhibition of DNA 
synthesis in the presence of a  suboptimal concentration (2 
ng/ml) of FGF also produced similar inhibition in the pres- 
ence of 100 times (200 ng/ml) excess FGE It is important 
to note that the concentration of PF-4 used here (a concentra- 
tion that produced 50%  inhibition)  was such that a  direct 
competition by FGF is expected to reverse the PF-4 effect. 
Taken together, these data suggest that the effect of PF-4 is 
not caused by inhibition of FGF action at the cell surface. 
These conclusions are also supported by a lack of effect on 
FGF-mediated smooth muscle cell growth (Fig.  1) as well as 
other  subsequent  studies  presented  in  a  later  section that 
show that the effect of PF-4 is on the events in the cell growth 
cycle. 
Inhibition by PF-4 is Reversible 
Inhibition of endothelial cell growth by PF-4 was not caused 
by cellular toxicity. Light microscopic examination of PF- 
4-treated cultures did not reveal any marked changes in cells 
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Figure 3. Inhibition of endothelial cell proliferation by PF-4 is not 
caused by competition with FGF: (A) Endothelial cells were plated 
in 12-well culture dishes, as described previously in the legend to 
Fig. 1, either in DME 10% serum (D) or EGM. Media were sup- 
plemented with 20 ng/ml of either FGF or ECGF. Cell growth was 
determined  after 4  d  by trypsinization  and  cell  counting  using 
Coulter counter. (B) Growth-arrested quiescent cells in 96-well mi- 
crotiter plates were transferred to fresh medium and then stimulated 
with varying concentrations of FGF in the absence (l) or presence 
(e) of 2 #g/ml PF-4. DNA synthesis during a 24-h incubation was 
determined  by [3H]thymidine incorporation. 
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Figure 4.  Reversibility  of PF-4  inhibition  of endothelial  cells. 
Confluent cultures of FBHE cells were transferred to fresh DME 
containing 10% FBS, 20 ng/ml FGF, and 2/zg/ml PF-4. After 24 h, 
cells were washed and then further incubated in the presence (o) 
or absence (B) of 2 #g/ml PF-4 for 24 h. A control cells (A) were 
without PF-4 throughout the 48-h incubation.  DNA synthesis was 
then determined by pulse labeling with [3H]thymidine at 3-h inter- 
vals. The data are mean of triplicates  +SD. 
morphology or detachment from the tissue culture plates. 
The lack of  toxicity was further demonstrated by a reversibil- 
ity of PF-4 actin  (Fig.  4).  Endothelial  cultures  were first 
treated with PF-4 for 24 h under the conditions described for 
the experiments in Figs.  1-3.  After 4  h, the cultures were 
washed three times with phosphate-buffered saline to remove 
PF-4. The cells were then incubated in the presence or ab- 
sence of PF-4. DNA synthesis and entry into S phase were 
determined by [3H]thymidine pulse labeling at 3-h intervals 
during the 4-h incubation. As shown in Fig. 4, incubation of 
endothelial ceils with PF-4 produced both inhibition of DNA 
synthesis and entry of cells into S phase.  Removal of PF-4 
by washing  and further incubation  resulted  in a  complete 
restoration of DNA synthesis. A  slightly higher DNA syn- 
thesis in washed cells could have been caused by a greater 
synchronization  of cells  previously  incubated  with  PF-4. 
These  results  demonstrate  that  the  effect of PF-4  on  en- 
dothelial cell growth is reversible. 
Site(s) of  PF-4 Action in the Cell Growth Cycle 
The site of PF-4-mediated cell cycle block was investigated 
by  [3H]thymidine pulse-labeling  studies.  Endothelial  cells 
were synchronized in G0/G1 phase by growing to confluence 
and by further incubation for 24 h in medium without FGF. 
The basal DNA synthesis in growth-arrested cells was only 
,,o8% of that achieved after FGF stimulation. FGF treatment 
of growth-arrested cells resulted in entry into S phase after 
•12  h and a 12-fold higher DNA synthesis than the controls 
after 18 h  (Fig.  5).  Addition of PF-4 during the cell cycle 
progression from G1 to S phase, i.e., at 0, 3, 6, and 9 h after 
FGF stimulation, resulted in >95 % inhibition of DNA syn- 
thesis.  PF-4 was able to block DNA synthesis when added 
1-2 h before entry of cells into S phase. These results clearly 
showed that PF-4 inhibited entry of cells into S phase.  An 
additional  intriguing  result  from this  experiment was  the 
effect of PF-4 on S phase cells. First, we noticed that in these 
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Figure 5.  Effect of PF-4 on cell cycle traverse from G0/G1 to S 
FBHE cells in 96-well microtiter  plates were growth arrested  in 
G0/G1 by growing to confluence and then subjecting to further in- 
cubation in FGF-free growth medium for 24 h. The cells were then 
washed and stimulated with 20 #g/ml FGE The effect of PF-4 on 
entry  into  S  phase  was  determined  by  pulse  labeling  with 
[3H]thymidine for 3-h intervals in cells receiving PF-4 at 0 (o), 3 
(B), 9 (A),  15 (*), and  18 (D) h. One set of cells were controls 
without  PF-4 (o). The data are average of triplicates  SD. Addi- 
tional data collected but not shown here for clarity of presentation 
were for the time points when PF-4 was added at 6, 12, and 24 h. 
cultures, PF-4 significantly (>50 %) reduced the basal DNA 
synthesis in residual cycling cells (Fig. 5, PF-4 added at 0 h). 
Second, addition of PF-4 to cells already progressing in S 
phase (15 and 18 h after FGF stimulation) also reduced DNA 
synthesis. In both cases, the reduction in DNA synthesis oc- 
curred within 1-3 h after PF-4 treatment. These results sug- 
gested that PF-4 may affect cells actively undergoing DNA 
synthesis. However, the apparent inhibition of DNA synthe- 
sis by PF-4 when added  during S  phase could also result 
from the inhibition of the entry of residual cells in S phase 
and/or exit of some cells from S phase. Therefore, although 
PF-4 appeared to have inhibited DNA synthesis in S phase 
cells,  further  investigation was  required  to clearly distin- 
guish a potentially direct effect of PF-4 on S phase cells from 
the reduction of DNA synthesis caused by influx and exit of 
cells from the S phase. 
To further characterize the cell cycle block points, we per- 
formed cell cycle analysis using FACS ~. Exponentially grow- 
ing cultures were treated with PF-4 for 40 h. The control and 
treated ceils were trypsinized, and DNA content was deter- 
mined by FACS ® analysis after propidium iodide  staining 
(Fig. 6). The data in Table I show that PF-4 treatment pro- 
duced a marked shift in the distribution of endothelial cells 
from G0/G1 to early S phase. The fraction of ceils in G0/G1 
were reduced from 56.74%  to 17.04%,  whereas fraction of 
cells in S phase increased from 28.64 % to 71.17 % upon PF-4 
treatment. No significant change was observed in the G2/M 
fraction. Hydroxyurea used as an internal control produced 
an expected effect by blocking cells in S phase. These data 
suggested  that  in  exponentially  growing  cultures  of  en- 
dothelial cells,  PF-4 blocked cells in early S phase. 
Effect of  PF-4 on S Phase Cells 
Further  direct evidence for the effect of PF-4 on S  phase 
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in Response to PF-4 
G0/G1  S  G2/M  CV 
Control  56.74  28.64  14.62  +4.13 
Hydroxyurea  1.45  63.71  34.84  +6.24 
PF-4  17.04  71.17  11.79  +6.92 
Distribution  of cells  in  GO/G1, S,  and  G'2/M was obtained  from the  data 
presented in Fig.  5 using the Modfit program.  CV, coefficient of variance. 
PF-4  immediately after the  removal of hydroxyurea pro- 
duced a complete inhibition of DNA synthesis. Fig.  7 also 
shows that treatment of cells with PF-4 at various times after 
hydroxyurea removal inhibited DNA synthesis within 1 h of 
its addition. For example, in control cultures, DNA synthesis 
reached ,,o  3. 5-fold at 4.5 h after removal ofhydroxyurea. Ad- 
dition of PF-4 at this point resulted in a 277 % lower DNA 
synthesis,  as  compared  to  the  untreated  controls  within 
1.5 h. DNA synthesis was reduced to basal level within 3 h 
after  PF-4  addition.  These  data  clearly  demonstrate  that 
PF-4 treatment directly inhibits DNA synthesis, as well as 
progression of ceils through S phase. 
Effect of Heparin on PF-4 Activity 
Heparin  is  an  important  modulator  of  endothelial  cell 
proliferation and binds PF-4 with high affinity. The effect of 
heparin on the cellular actions of PF-4 is not yet fully under- 
stood.  We have examined  the  effect of heparin  on  PF-4- 
mediated inhibition of endothelial cell proliferation, as well 
as DNA synthesis in S phase cells.  FBHE cells were incu- 
bated with 1 U/ml of heparin in the absence or presence of 
PF-4.  Cell growth or DNA synthesis in cells synchronized 
in S phase by hydroxyurea was then determined. As before, 
PF-4 treatment inhibited cell proliferation and DNA synthe- 
sis in S phase-synchronized cells (Fig. 8). Addition of hepa- 
rin  alone produced  •40%  reduction  in  cell proliferation. 
Figure 6. PF-4 induces accumulation of  endothelial cells in S phase. 
FBHE cells were plated as triplicates at a cell density of 5  x  104 
cells per well in six-well tissue culture dishes in DMEM containing 
10% serum and 20 ng/ml FGE Duplicate wells were treated with 
(A~ none, (B) 2 #g/ml PF-4, or (C) I mM hydmxyurea. After 40 h, 
cells were processed for pmpidium iodide staining and FACS  ®  anal- 
ysis. Cell distribution of  G0/G1, S, and G2/M was determined using 
the Varity Modfit program. From left to right, the areas under the 
first dark peak, the  gray peaks,  and the  second  dark peak cor- 
respond to GO/G1, S, and G2/M, respectively. 
progression  was  obtained  by  using  endothelial  cells  syn- 
chronized in S phase. As shown previously in Fig. 6, incuba- 
tion  of endothelial  cells  in  the  presence  of hydroxyurea 
resulted in an accumulation of cells in S phase. Under these 
conditions,  >62 % of the cells in culture were accumulated 
in S phase. More importantly, only <1.5 % cells were in the 
G0/G1 phase (Table I), therefore enabling us to dissect the 
effect of PF-4 on G1 and S phases. Removal of hydroxyurea 
by washing resulted in a prompt resumption of DNA synthe- 
sis leading to a five- to sixfold increase in DNA synthesis, 
as compared to the unwashed controls (Fig. 7). Addition of 
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Figure 7. Inhibition of DNA synthesis in S phase cells by PF-4. 
Sparse cultures  of FBHE cells were synchronized in S phase by 
treatment with hydmxyurea,  as described  in the legend to Fig. 6. 
After 24 h, hydroxyurea was removed by washing twice in DME 
containing  10% serum. PF-4 (2 #g/ml) was then added at 0 (A), 
3 (o), 4.5 (v), and 6 (o) h after washing. Also shown are the con- 
trol cells without removal of hydroxyurea (--)  and washed cells 
without  PF-4 treatment  (e).  DNA synthesis was determined  by 
[3H]thymidine pulse labeling for 1.5-h intervals. 
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proliferation was determined by incubation of FBHE cells in DME 
containing 10% FBS, 20 ng FGF, and 2/zg/ml PF-4 in the presence 
or absence of 1 U/ml heparin. Cell growth was determined after 
4 d. (B) Effect of heparin on DNA synthesis in S phase cells was 
determined by incubation of cells in  1 mM hydroxyurea, as de- 
scribed in the legend to Fig. 7. Hydroxyurea was then removed by 
washing, and the cells were incubated with 2 #g/ml PF-4 in the 
presence or absence of 1 U/ml heparin. DNA synthesis was deter- 
mined by [3H]thymidine  incorporation at the end of a 24-h incuba- 
tion. The controls were without PF-4 or heparin. 
Addition of heparin to PF-4-treated cells resulted in a rever- 
sal of inhibition of cell proliferation by PF4. Similarly, hepa- 
rin treatment antagonized the inhibition of DNA synthesis by 
PF-4 in cells synchronized in S phase. These results demon- 
strate that  heparin antagonizes the effect of PF-4  on cell 
proliferation and DNA synthesis. 
Discussion 
Recent studies have demonstrated that iaF-4, an archetype of 
"chemokine" superfamily of genes, is an important modu- 
lator of endothelial cell proliferation (16, 17,  28).  Unlike 
TGF-/~ or TNF, which inhibit endothelial cell proliferation 
in vitro but stimulate angiogenesis in vivo, PF-4 is a unique 
endogenous modulator that inhibits endothelial cell growth 
in vitro, as well as angiogenesis in vivo (16, 17, 28). How- 
ever, at the present time, very little is known about the mech- 
anism of action of PF-4 on endothelial cells. Our studies, for 
the first time, have revealed a unique mode of action of PF-4 
on cell cycle progression in endothelial cells. We have shown 
that PF-4 inhibited proliferation of endothelial ceils derived 
from large and microvessels. Growth inhibition by PF-4 oc- 
curred without altering the doubling time of the exponen- 
tially growing endothelial cell population,  suggesting that 
the effect of PF-4 was not simply caused by delaying of cell 
division. Growth inhibition by PF-4 was not caused by cyto- 
toxicity. During an extended incubation of endothelial cells, 
smooth muscle cells, or fibroblasts with PF-4, no discernible 
morphological change or detachment of cell monolayer was 
observed. Furthermore, cell growth inhibition by PF-4 was 
reversed  upon  washing  the  cultures.  For  vascular  cells, 
growth inhibition by PF-4 appeared selective for endothelial 
cells.  Growth  of vascular  smooth  muscle  cells  was  not 
affected by PF-4. 
Our initial evidence suggested that cell growth inhibition 
by  PF-4  is  mediated  by  blocking  intracellular  cell  cycle 
events. For example, endothelial cell growth inhibition was 
independent of the nature of the growth stimuli used. Growth 
inhibition of a FGF-dependent endothelial cell line was not 
abrogated by excess FGE Growth of vascular smooth muscle 
cells  stimulated  with  FGF  (growth  factor  used  for  en- 
dothelial cells) was not inhibited by PF-4. Finally, PF-4 was 
equally effective when added 8-10 h after FGF stimulation 
of endothelial cells. 
A  most striking action of PF-4 is its effect on cell cycle 
progression from G1  to S  and on S-phase cells.  By [3H]- 
thymidine  pulse-labeling  studies  in  G0/Gl-synchronized 
confluent cultures, we have demonstrated that PF-4 blocked 
entry of cells into S phase when added during the traverse 
of endothelial cells from G1 to S. In addition, PF-4 reduced 
DNA synthesis in cells that were already in S phase. Inhibi- 
tion of endothelial cells in S phase was further confirmed by 
flow cytometry. In  exponentially growing  cultures  of en- 
dothelial cells, treatment with PF-4 resulted in accumulation 
of >70% cells in early S phase. Further direct confirmation 
of  the inhibition of S phase progression by PF-4 was obtained 
from cells synchronized in S  phase by hydroxyurea treat- 
ment.  Incubation  of  endothelial  cells  with  hydroxyurea 
produced inhibition of DNA synthesis, aswell as accumula- 
tion of cells in  S  phase.  Removal of. hydroxyurea from S 
phase-arrested cells by washing resulted in an immediate 
resumption of DNA  synthesis.  Treatment with PF-4 after 
hydroxyurea removal blocked resumption of DNA synthesis. 
Furthermore,  PF-4  also  inhibited DNA  synthesis  in  cells 
progressing in S phase after release from hydroxyurea  arrest. 
Heparin  has  been  shown  to  enhance  endothelial  cell 
proliferation (25), whereas it inhibits vascular smooth mus- 
cle cell proliferation (4). The COOH-terminal ot helix region 
of PF-4 contains a lysine-rich domain that has been impli- 
cated in heparin binding (14).  An analogue of recombinant 
PF-4 lacking a lysine residue and the heparin-binding activ- 
ity was found equally effective as an inhibitor of endothelial 
cell proliferation (17), suggesting that heparin binding is not 
essential for PF-4 activity on endothelial cells. Our results 
show  that  addition of heparin to the  culture medium an- 
tagonizes the effect of PF-4 on cell proliferation, as well as 
DNA synthesis in S phase cells. 
The effect of PF-4 on S phase progression is unique as 
compared to the mode of action of the previously known 
cytokines  inhibiting  endothelial  cell  proliferation.  TNF- 
mediated cell growth inhibition occurs in the G2 phase of the 
cell growth cycle (6). TGF-/3, another potent inhibitor of en- 
dothelial cell proliferation in vitro, blocks cells in late G1 
phase (12,  29). Also, unlike PF-4, the activity of TNF and 
TGF-B is not restricted to endothelial ceils.  Both of these 
cytokines inhibit fibroblasts, smooth muscle cells, and a va- 
riety of tumor cells. Furthermore, in contrast to PF-4, TNF 
and TGF-~ promote angiogenesis in vivo (9, 26). The site of 
cell cycle block by another endothelial cell growth inhibitor 
protein known as SPARC is also in G1 phase (11). The char- 
acterization of the biological functions and mode of action 
of the chemokine family of peptides are currently under in- 
tense  investigation.  Furthermore,  since  the  cell  growth- 
modulating activity of the chemokines such as PF-4, IL-8, 
and MIP-ct  is only a  recent finding, it remains to be seen 
whether  S  phase  inhibition  is  specific  for  PF-4  or  it 
represents a unique mode of action of the chemokine super- 
gene family. In this regard, a recent observation suggesting 
an effect  of MIP-ot on S phase progenitor cells is very intrigu- 
ing (18). The mode of PF-4-mediated cells growth inhibition 
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spect to the potential molecular targets  affected by  PF-4. 
It  was  recently  shown  that  cyclin  E  (7,  23)  and  cyclin- 
dependent  kinase  cdc-2  (5,  8,  19)  play  important role in 
progression of cells from G1 to S, as well as in S phase. Fur- 
ther studies will examine the molecular mechanism of PF-4 
action, including its effects on cyclin/cyclin kinases regulat- 
ing the G1 and S phases of endothelial cells. 
Formation of new blood vessels is a highly controlled pro- 
cess. Under physiological conditions, new blood vessels are 
formed  during  embryonic  development,  leutinization,  or 
wound healing.  However, neovascularization is widely as- 
sociated with a variety  of pathologies, including neoplasia, 
atherosclerosis, diabetic retinopathy,  psoriasis, rheumatoid 
arthritis,  inflammation, and accelerated vascular disease af- 
ter angioplasty or coronary artery bypass graft.  A very im- 
portant aspect of PF-4 activity is the inhibition of endothelial 
cell proliferation in vitro, as well as angiogenesis in vivo (16, 
17).  This unique activity of PF-4 has shown promise for the 
treatment of angiogenic diseases. In preclinical mice models, 
injections of recombinant PF-4 to primary cutaneous im- 
plants  of B-16(F10)  melanoma  and  HTC-116  colon carci- 
noma have shown dramatic reduction in tumor size that was 
accompanied by significant increase in survival rate (16, 17). 
The unique effect of PF-4 on cell cycle progression and fur- 
ther  understanding  of  the  mechanism  of  action  on  en- 
dothelial cells could ultimately lead to the development of 
novel targets  for antiangiogenic therapies in the future. 
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